Skip NavigationSkip to Content
Return Return to Search Results

Heightened systemic levels of anti-inflammatory cytokines in pulmonary tuberculosis and alterations following anti-tuberculosis treatment

  1. Author:
    Moideen, Kadar
    Kumar, Nathella P
    Bethunaickan, Ramalingam
    Banurekha, Vaithilingam V
    Nair, Dina
    Babu, Subash

  2. Author Address

    National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India., National Institute for Research in Tuberculosis, Chennai, India., National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India; LPD, NIAID, NIH, Bethesda, MD, USA; Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD, USA. Electronic address: sbabu@mail.nih.gov.,
    1. Year: 2020
    2. Date: Mar
    3. Epub Date: 2019 12 04
  2. Journal: Cytokine
    1. 127
    2. Pages: 154929
  4. Type of Article: Article
  5. Article Number: 154929
  6. ISSN: 1043-4666
  1. Abstract:

    Pro-inflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis (PTB). However, the association of Type 2, regulatory and other anti-inflammatory cytokines with disease severity and bacterial burden in PTB is not well understood. To examine the association of anti-inflammatory cytokines with PTB, we examined the plasma levels of Type 2 (IL-4, IL-5, IL-13), regulatory (IL-10, TGFß) and other anti-inflammatory (IL-19, IL-27, IL-37) cytokines in individuals with PTB, latent TB (LTB) or healthy controls (HC). We also examined the plasma levels of these cytokines in PTB individuals following anti-tuberculosis therapy (ATT). PTB individuals exhibited significantly higher plasma levels of IL-4, IL-13, IL-10, IL-19 and IL-27 in comparison to LTB and HC individuals and of TGFß in comparison to HC individuals. In contrast, PTB individuals exhibited significantly lower plasma levels of IL-5 and IL-37 in comparison to both LTB and HC individuals. PTB individuals with bilateral or cavitary disease did not exhibit significantly different plasma levels of these cytokines in comparison to those with unilateral or non-cavitary disease nor did the cytokines exhibit any significant relationship with bacterial burdens. Finally, following ATT, the plasma levels of IL-4, IL-5 and IL-10 were significantly decreased, while the plasma levels of IL-13 and IL-37 were significantly increased in PTB individuals. Therefore, our data demonstrate that PTB is associated with altered levels of Type 2, regulatory and other anti-inflammatory cytokines, some of which are altered followed chemotherapy. Our data also reveal that anti-inflammatory cytokines are not markers of disease severity or bacterial burden in PTB. Elevations in anti-inflammatory cytokines might help prevent the detrimental effects of pro-inflammatory responses in PTB. Published by Elsevier Ltd.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.cyto.2019.154929
  3. PMID: 31811994
  4. View record in Web of Science®
  5. WOS: 000515418400019
  6. PII : S1043-4666(19)30358-8

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel